Benufutamab

立即咨询

Benufutamab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2109730-69-8

GEN1029

Benufutamab (GEN1029) 是一种死亡受体 5 (DR5) 特异性激动性抗体。Benufutamab 是 2 种非竞争性 DR5 特异性 IgG1 抗体的混合物，每种抗体的 Fc 结构域都有一个 E430G 突变。Benufutamab 具有抗肿瘤作用。

生物活性

Benufutamab (GEN1029) is adeath receptor 5(DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specificIgG1antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects^[1].

体外研究
(In Vitro)

Benufutamab (GEN1029; HexaBody-DR5/DR5; 20 μg/mL; 24 hours) induces potent cytotoxicity in multiple myeloma (MM) cells^[1].

Cell Viability Assay^[1]

Cell Line:	Multiple myeloma (MM) cells
Concentration:	20 μg/mL
Incubation Time:	24 hours
Result:	Induced potent cytotoxicity.

体内研究
(In Vivo)

Benufutamab (GEN1029; HexaBody-DR5/DR5; 0.5-2 mg/kg; i.p.; once a week; for 9 weeks) shows significant antitumor activity in PDX models for colorectal cancer^[2].

Animal Model:	Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells^[2]
Dosage:	0.5 mg/kg, or 2 mg/kg
Administration:	i.p.; once a week; for 9 weeks
Result:	Showed significant antitumor activity.

CAS 号

2109730-69-8

中文名称

贝奴妥单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.